Beyond Restasis: Allergan buys Oculeve dry eye device
This article was originally published in Scrip
Executive Summary
Allergan, whose blockbuster Restasis (cyclosporine) is the only approved prescription dry eye drug in the US, is buying the device maker Oculeve for $125m to diversify the company's position in the market.